Davide Ramoni

🫀 Despite modern therapies, residual cardiovascular risk remains high.
JCAD emerges as a promising target to address residual CV risk in patients with acute coronary syndrome.
📖 Read our publication in European Heart Journal 🚀 @ehj_ed @escardio academic.oup.com/eurheartj/arti…

@escardio Fund Basic Science Course 2026 in Nice 🇫🇷 is over and I already miss it 🫀🔬
Honoured to be selected as 1 of 50 awardees from 757 applications across 101 countries. Deep gratitude to Prof. Cinzia Perrino, Paul Evans, ESC staff, and everyone I had the chance to meet.

The time is coming! 🚀
Excited to be among the 50 fellows joining the ESC Fund #BasicScienceCourse2026 in Nice 🇫🇷 Looking forward to learning from leading experts in cardiovascular research and connecting with scientists across Europe. Grateful to @escardio for this opportunity!

Very good time in Lisbon for European Society for Clinical Investigation 2026 ASM 🇵🇹
Science, networking, collaboration, and a beautiful city to host it all. Looking forward to the next edition in Coimbra! 🔬

🫀 A major avenue for cardiovascular research ahead.
JCAD emerges as a promising target to tackle residual cardiovascular risk in ACS patients.
📖 Read our publication in European Heart Journal
🔗 academic.oup.com/eurheartj/adva…
#HeartHealth #Research #Cardiology